Overview of Aknemycin Plus

Property	Description
Active Ingredients	Erythromycin, Tretinoin
Form	Cutaneous Solution (Topical liquid)
Pharmacological Class	Topical Antiinfective & Topical Retinoid
Common Use	Management of Acne Vulgaris
Origin	Semi-synthetic / Synthetic Combination

Aknemycin Plus is a specialized prescription-only, fixed-dose combination medication formulated as a Cutaneous Solution, intended for topical use on the skin. This product is distinct from single-agent treatments because it combines two active pharmacological agents in a single liquid preparation, a strategy clinically recognized for addressing the dual etiology of acne. It is formally classified as a combination product integrating a macrolide antibiotic with a potent topical retinoid.

Active Composition: Erythromycin and Tretinoin

The product's identity is defined by its two International Nonproprietary Name (INN) components: Erythromycin and Tretinoin. Erythromycin is a semi-synthetic antibiotic, while Tretinoin is a synthetic retinoid, a derivative of Vitamin A acid. Tretinoin is used to address skin cell growth and differentiation. The solution utilizes an alcoholic solution base containing excipients like Ethanol and Glycerol, which aids in the application and penetration of the actives.

General Therapeutic Purpose

The general therapeutic purpose of Aknemycin Plus is the management of acne vulgaris, particularly in patients presenting with both non-inflammatory and inflammatory lesions. The product is designed to leverage the antibacterial capabilities of Erythromycin to reduce microbial load, while the Tretinoin component works to normalize follicular keratinization. As an anti-acne preparation, this dual mechanism ensures the product simultaneously addresses the microbial contribution and the physical pore obstruction, the main drivers of the condition.

Regulatory References

MedlinePlus, notes that Tretinoin is primarily used to address skin cell growth and differentiation

What side effects are possible with Aknemycin Plus?

Possible side effects and safety information

Official regulatory documentation structures the safety profile of Aknemycin Plus (Erythromycin/Tretinoin topical solution) around reactions primarily involving the skin and specific systemic constraints.

Adverse Reaction Classifications

The most commonly anticipated adverse reactions are classified as Skin and Subcutaneous Tissue Disorders. These typically include local effects such as erythema (redness), desquamation (peeling), dryness, and a burning sensation at the application site. While severe reactions are uncommon, the product label documents the potential for Immune System Disorders, including serious hypersensitivity reactions and, with a frequency classified as not known, the rare occurrence of Acute Generalised Exanthematous Pustulosis (AGEP).

Classification	Examples of Reactions
Skin and Subcutaneous Tissue Disorders	Erythema, Desquamation, Dryness, Burning Sensation, Temporary Skin Discoloration
Serious Adverse Reactions	Severe Hypersensitivity Phenomena, Theoretical Risk of Antibiotic-Associated Colitis

Time- and Population-Specific Safety Notes

The intensity of local skin irritation, including burning and peeling, is noted in regulatory documents to be more pronounced during the initial treatment phase and usually subsides with continued use. Furthermore, an apparent worsening of the acne at the commencement of therapy is recognized as a typically transitory effect.

Due to the Tretinoin component, the solution carries mandatory contraindications for specific populations: it is formally prohibited for use by pregnant women or women who are planning to conceive. Use is also strictly avoided during breastfeeding.

Safety Restrictions

Safety limitations listed in official documentation restrict the use of this product in patients with certain pre-existing conditions, including acute eczemas, rosacea, acute inflammatory skin conditions, and underlying sunburn. Caution is also noted regarding the high concentration of Ethanol (752 mg/mL), which poses a flammability risk and contributes to local irritation.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documentation outlines distinct considerations for overdose based on the route of exposure to the Erythromycin and Tretinoin cutaneous solution. All actions described are mandated by official prescribing information.

Overdose Manifestations and Required Actions

Exposure Context	Documented Manifestation or Risk	Immediate Action Required
Topical Over-application	Systemic toxicity is unlikely to occur. Localized symptoms such as marked erythema, drying, and discomfort may result.	Reduce application frequency; manage symptoms.
Accidental Oral Ingestion	Risk associated with the amount ingested; requires procedural intervention.	Seek immediate medical attention; gastric lavage is required for non-small amounts.

Official Regulatory Statements

Official labeling states that systemic toxicity from applying too much of the solution is unlikely because the amount of active ingredients absorbed into the body is too small. The principal risk requiring emergency medical intervention is accidental oral ingestion. Immediate medical attention must be sought in this scenario. Following ingestion of a non-small amount, the regulatory procedure specifies that gastric lavage should be performed as soon as possible. No specific antidote is documented in the official prescribing information for this overdose.

Therapeutic Uses of Aknemycin Plus

What Aknemycin Plus Treats: Main Uses and Benefits

This solution is commonly used for managing acne vulgaris in conditions presenting with systemic or localized discomfort, particularly when the patient exhibits a blend of symptoms: non-inflammatory spots like blackheads and whiteheads, and symptoms related to inflammatory or irritative states such as papules and pustules. This combined management strategy is relevant across a broad range of acne manifestations, which helps address symptom clusters and eases the overall symptom burden.

This treatment is considered relevant for adolescents and adults with mild to moderate acne severity. It contributes to preventing the recurrence of breakouts and offers symptomatic relief that helps patients cope more steadily with challenging acne episodes. The medication assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

“This solution is generally applied when patients require integrated topical support for both blockage and inflammation.”

Quick Fact: Relief for Mixed Acne Symptoms

Quick Fact: Relief for Mixed Acne Symptoms

The solution is applied in addressing the broad range of manifestations from occlusive lesions to inflammatory spots. In situations where patients experience recurrence, it may help ease the impact of inflammation on skin texture, providing supportive relief.

Regulatory References

Israel Ministry of Health Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Scope

Populations for Whom Use is Allowed:

The solution is generally permitted for use by adults and adolescents over the age of 12 years.

Populations for Whom Use is Contraindicated:

Classification	Rule as Stated in Regulatory Documents
Pregnancy	Contraindicated in women who are pregnant or planning a pregnancy (due to the Tretinoin component).
Hypersensitivity	Contraindicated in patients allergic to Erythromycin, Tretinoin, or any other ingredient in the formulation.
Concurrent Skin Conditions	Contraindicated in patients with rosacea, acute eczema, perioral dermatitis, or severe sunburn.
Comorbidity	Contraindicated in individuals with a family or personal history of cutaneous epithelioma (a type of skin tumor).
Age Restriction	Contraindicated in children under 12 years old (use not established).

Official Eligibility Statements:

Use is not recommended during breastfeeding (lactation); if use is deemed necessary, the product must not be applied to the breast area to prevent direct contact with the infant. Treatment must be immediately discontinued if a patient becomes pregnant while using the medicine. The official eligibility profile uses the terms contraindicated and not recommended to define population restrictions, ensuring strict adherence to safety mandates defined by regulatory agencies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Aknemycin Plus (Erythromycin and Tretinoin) based on restrictions related to antagonism, cumulative irritancy, and systemic toxicity risk from the active components.

Drug–Drug Interaction Restrictions

Interacting Product Category	Official Interaction Outcome	Regulatory Restriction
Lincosamide Antibiotics (e.g., Clindamycin)	Antagonism demonstrated in vitro with the Erythromycin component.	Co-administration is restricted.
Oral Tetracyclines	Increased risk of intracranial pressure (Pseudotumor Cerebri) from the Tretinoin component.	Co-administration is restricted.
Oral Vitamin A Preparations	Risk of aggravating symptoms of hypervitaminosis A from the Tretinoin component.	Co-administration is restricted.
Potent CYP Enzyme Inhibitors	May increase systemic Tretinoin plasma concentrations, increasing toxicity risk.	Caution is advised.

Topical and Product Interactions

Interactions related to the Tretinoin component primarily involve pharmacodynamic effects on the skin. Co-administration with other topical acne preparations, particularly keratolytic agents such as Benzoyl Peroxide, Sulfur, Resorcinol, or Salicylic Acid, is subject to caution due to the documented risk of cumulative local irritancy. Official advice includes allowing the skin to “rest” until the effects of these peeling preparations subside before use of this product is initiated.

Additionally, products with strong drying effects, including certain cleansers and cosmetics, or those with high concentrations of alcohol, spice, or lime, are restricted due to the potential for interaction and heightened skin irritation.

Mechanism of Action

Normalization of Follicular Architecture via Retinoid Receptor Activation

This domain describes the action of Tretinoin, which functions as an agonist for Retinoic Acid Receptors (RARs) inside the nucleus of skin cells. This molecular interaction modulates the genes governing keratinocyte differentiation and reduces the excessive stickiness of cells. The resulting physiological effect is the accelerated and normalized shedding of follicular epithelial cells, leading to the reduction and prevention of follicular plugs.

Dual Suppression of Microbial Proliferation and Inflammation

Erythromycin operates by reversibly binding to the 50S ribosomal subunit of susceptible bacteria, such as Cutibacterium acnes, thereby inhibiting the synthesis of bacterial proteins. This suppression of the bacterial population limits the downstream production of microbial pro-inflammatory mediators. The two active agents also provide convergent anti-inflammatory action: Tretinoin down-regulates inflammatory pathways, while Erythromycin exerts a direct anti-inflammatory effect, contributing to the dampening of the inflammatory signaling cascade.

Complementary Dual-Action Pathophysiology

The overall mechanistic effect leverages a synergy where the structural normalization of the follicle (Tretinoin) facilitates deeper diffusional access for the microbial suppressor (Erythromycin). This combined action addresses two distinct biological factors: the structural modification of follicular architecture and the suppression of microbial activity.

Dosage and Administration Information

Aknemycin Plus is administered exclusively via the topical route as a Cutaneous Solution, which contains the active ingredients erythromycin 4% and tretinoin 0.025%. This administration method is specified for application directly onto the affected areas of the skin.

The standard administration schedule involves applying a thin layer of the solution once or twice daily. To ensure proper usage, the solution is to be applied to skin that has been cleansed prior to use, and excessive application should be avoided. Consistent application over the entire course is a key procedural component, with the standard usage regimen generally applicable to both adults and adolescents over 12 years of age.

The period of use is defined and should generally not exceed twelve weeks in total duration, with a typical course lasting between nine and twelve weeks.

Specific procedural instructions must be followed during application. The solution, which utilizes an alcoholic base, is flammable, necessitating caution to avoid heat or flames until the product has dried completely. Furthermore, the application must prevent contact with sensitive areas, including the eyes, lips, nostrils, and any skin folds. The official procedure outlines that the product is applied directly from the special applicator bottle, and hands should be washed immediately if contact occurs.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aknemycin Plus

Evidence for use in Mild to Moderate Acne Vulgaris

The research base for this combination treatment was evaluated in multiple Randomized Controlled Trials (RCTs), and the findings are included in several Systematic Reviews and Meta-Analyses. These studies focused primarily on individuals diagnosed with mild to moderate acne vulgaris. Researchers designed trials to evaluate outcomes related to the numbers of both non-inflammatory lesions (such as blackheads and whiteheads) and inflammatory lesions (such as papules and pustules).

Research explored how patients’ overall skin condition was monitored in the observed populations over the study period, often using standardized clinical scales to assess the global severity of the acne. Findings describe patterns observed in the studies where this combination was evaluated in conditions marked by the presence of these mixed lesion types. The evidence contributes to understanding symptom patterns observed in groups of patients with mild to moderate acne under defined research conditions.

Comparative Trial Findings

Research examined how the combination of erythromycin and tretinoin was evaluated alongside other topical acne treatments available. Large-scale analytical research, such as systematic reviews, was studied to contribute to the broader evidence landscape in the field of topical acne management. Studies were observed in settings where researchers evaluated the combination solution directly alongside its individual components (Erythromycin or Tretinoin used separately). This comparative research contributes to the broader evidence landscape by describing the outcomes seen with the dual-ingredient approach relative to single-ingredient options.

Long-Term Studies and Follow-up Data

Most of the primary clinical research for this treatment was conducted during periods of increased symptom activity and focuses on a relatively short-term assessment, typically measuring outcomes at up to 12 weeks. As a result, the follow-up durations were limited.

Currently, there is limited information for long-term outcomes that monitor the durability of patterns observed or the rate of acne recurrence after the initial treatment period. The research explored short-term symptom changes, but long-term effects are not fully established regarding durability of effect after a course of treatment is completed. This area remains a key gap in the evidence.

Evidence in Special Populations

The research that served as the foundation for the regulatory evaluation of this treatment primarily focused on the core indicated group: individuals with mild to moderate acne. The study populations included adolescents (typically age 12 and older) and adults. This means the results apply only to the populations studied and provide context for these age groups. However, data for certain groups remain insufficient, which includes older adults, pregnant patients, or children younger than 12 years of age.

What is Still Uncertain About Aknemycin Plus Research

Research highlights what is known — and what is still uncertain — about this type of topical antibiotic combination treatment. A major area of scientific focus is the research concern regarding the potential for bacterial resistance developing against the Erythromycin component over time. Furthermore, because the follow-up durations were limited in the principal trials, there is limited information for long-term outcomes such as maintenance of favorable clinical assessment scores or recurrence rates over extended periods. The overall evidence provides context but not individual predictions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Aknemycin Plus (FAQ)

Q: Is Aknemycin Plus available over the counter?

According to the product's classification by health authorities, Aknemycin Plus is formally designated as a prescription-only medicine. This means that access requires authorization from a healthcare professional.

Q: Can Aknemycin Plus make my skin more sensitive to the sun?

Yes, official patient information notes that the skin may become more sensitive to UV light during treatment due to the Tretinoin component. For this reason, regulatory documents advise avoiding activities like sunbathing, using sunbeds, or sunlamps while undergoing therapy.

Q: Is it normal to feel a slight stinging sensation when applying Aknemycin Plus?

Official documents list a burning sensation as a possible local side effect at the application site. This sensation is often associated with the product’s alcoholic solution base. Official information indicates this localized effect may be more pronounced when treatment is first started.

Q: What types of birth control might interact with Aknemycin Plus?

The Tretinoin component in Aknemycin Plus is a type of retinoid. Official information states that related substances, when used orally, are noted to potentially reduce the efficacy of low-dose progestogen contraceptives. However, the same documents describe this as not affecting combined oral contraceptives.

Q: Are there any long-term side effects associated with Aknemycin Plus?

Regulatory guidance defines a maximum treatment period that generally should not exceed twelve weeks in total duration. Since official research studies are primarily based on short-term assessments, the available information on outcomes or side effects for use extending beyond this period is limited.

Q: Is Aknemycin Plus known to cause skin dryness or peeling?

Yes, common local effects listed in the product's safety information include dry skin and peeling (also known as desquamation) at the application site. The intensity of this local irritation is noted to be more pronounced when treatment is first initiated.

Q: Can I use makeup shortly after applying Aknemycin Plus?

Official documentation advises restricting the use of certain products that can increase skin irritation. This caution specifically includes avoiding cosmetics with strong drying effects due to the potential for interaction and heightened local sensitivity.

Q: Can I use other acne treatments at the same time as Aknemycin Plus?

Co-administration with certain other topical acne treatments is subject to caution. Official documents note that using the solution with keratolytic agents such as Benzoyl Peroxide, Sulfur, or Salicylic Acid increases the risk of cumulative local irritancy.

Q: Is it normal for acne to look worse before it gets better with Aknemycin Plus?

Official safety notes recognize an apparent worsening of acne at the start of therapy as a typically transitory effect. This temporary effect is recognized in official safety notes and is expected to pass.

Q: Do regulatory bodies consider Aknemycin Plus to be safe for long-term use?

Regulatory guidance defines a maximum period of use that generally should not exceed twelve weeks. The research evidence supporting its use is primarily based on short-term assessment. Consequently, the official information regarding the durability of effects and outcomes of use over extended periods is limited.

Q: How quickly can I expect to see any changes after starting Aknemycin Plus?

Official information notes that improvement may not be immediately visible, sometimes taking several weeks after starting the solution. However, a marked improvement is often observed in the study populations within four weeks of initiating treatment.

Q: What is the difference between Aknemycin Plus and regular Aknemycin?

Aknemycin Plus is classified as a fixed-dose combination product. It contains two active ingredients: the antibiotic Erythromycin and the retinoid Tretinoin, making it distinct from single-agent formulations.

Q: Can Aknemycin Plus be used on parts of the body other than the face?

The official product procedure specifies that the solution should be applied directly onto the affected areas of the skin where acne vulgaris is diagnosed.

Q: What if I forget to apply Aknemycin Plus one time?

The official instructions describe the procedure for a missed dose: the forgotten application should be used as soon as it is remembered. Importantly, the instructions state not to apply a double amount of the solution to compensate for the forgotten application.

Q: Is Aknemycin Plus effective for cystic acne?

The research evidence used for regulatory evaluation focuses primarily on individuals diagnosed with mild to moderate acne vulgaris. Data regarding severe forms of acne, such as cysts or nodules, is not included in the primary evidence base.

Q: Does using Aknemycin Plus increase the risk of antibiotic resistance?

The potential for bacterial resistance developing against the Erythromycin component over time is highlighted in official research overviews as a major area of scientific focus and concern. This is a known consideration for topical antibiotic combination treatments.

How should Aknemycin Plus be stored and disposed of?

How to Store and Dispose of Aknemycin Plus?

Storage Requirements

The cutaneous solution must be stored at a temperature below 30 C or below 25 C, depending on the labeled instructions. It is mandatory to keep the medicine in the outer carton to protect it from light, which is a known stability constraint. Due to its alcoholic base, the product is labeled as flammable and must be kept away from sources of ignition and fire. It must be secured out of the sight and reach of children at all times.

Disposal Instructions

Do not throw away unused or expired Aknemycin Plus via wastewater or household garbage. Patients are required to ask a pharmacist how to dispose of the medicine or follow local regulatory requirements for waste material disposal.

Aknemycin Plus